Jordyn Sava is an editor for Targeted Oncology.
Olaparib With High-Dose Chemo and ASCT Shows Potential in R/R Lymphomas
August 18th 2023In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.
Zilovertamab With Ibrutinib Provides Durable Responses in MCL and CLL
August 9th 2023In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.
Although Promising, CAR T-Cell Therapy in T-ALL Carries Many Challenges
August 5th 2023Though chimeric antigen receptor T cells are showing promise in T-cell acute lymphoblastic leukemia, challenges, including those related to manufacture, those that are patient/disease specific, and those regarding risk mitigation, remain a struggle.